FY2024 Earnings Estimate for ORKA Issued By Leerink Partnrs

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Analysts at Leerink Partnrs dropped their FY2024 earnings estimates for shares of Oruka Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of ($1.56) for the year, down from their previous forecast of ($1.33). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.50) per share. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at ($1.96) EPS and FY2027 earnings at ($1.99) EPS.

Other equities analysts have also recently issued reports about the company. TD Cowen initiated coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating for the company. Leerink Partners assumed coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective for the company. Wedbush assumed coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective for the company. Lifesci Capital began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Thursday, October 31st. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Stock Down 12.1 %

Shares of NASDAQ ORKA opened at $21.13 on Monday. The firm has a market capitalization of $25.53 million, a price-to-earnings ratio of -3.38 and a beta of 0.87. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88. The company has a fifty day moving average price of $26.76.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics during the third quarter worth approximately $1,037,000. FMR LLC bought a new position in shares of Oruka Therapeutics during the third quarter worth approximately $114,763,000. Great Point Partners LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter worth approximately $12,614,000. Braidwell LP bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $12,640,000. Finally, Janus Henderson Group PLC acquired a new position in Oruka Therapeutics in the 3rd quarter valued at $5,840,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.